Size indication Sample Clauses

Size indication. The dynamic tests shall be conducted with the largest dummy and the smallest dummy as defined in the following tables according to the size range indicated by the manufacturer for the Enhanced Child Restraint System. Table 8 Selection criteria for the dummy according to the range Size range indication (in cm) ≤ 60 60 < x ≤ 75 75 < x ≤ 87 87 < x ≤ 105 105 < x ≤ 125 >125 1 No lateral impact test using the Q10 dummy is required for i-Size booster seats with a size range upper limit between 125 cm and 135 cm. 2 ECRS shall not be approved only on the base of Q3 test results in non-integral configuration Where the Enhanced Child Restraint System requires substantial modification for different sizes (e.g., convertible Enhanced Child Restraint System) or if the size range cover more than 3 size ranges a relevant intermediate dummy(ies) shall be tested in addition to the dummy(ies) defined above.
Sample 1Sample 2Sample 3See All (8)
AutoNDA by SimpleDocs
Size indication. The dynamic tests shall be conducted with the largest dummy and the smallest dummy as defined in the following tables according to the size range indicated by the manufacturer for the Enhanced Child Restraint System. Table 7 Selection criteria for the dummy according to the range Size range indication (in cm) ≤ 60 60 < x ≤ 75 75 < x ≤ 87 87 < x ≤ 105 105 < x ≤ 125 >125
Sample 1Sample 2Sample 3See All (7)
Size indication. The dynamic tests shall be conducted with the largest dummy and the smallest dummy as defined in the following tables according to the size range indicated by the manufacturer for the Enhanced Child Restraint System. Table 7 Selection criteria for the dummy according to the range Size range indication (in cm) ≤ 60 60 < x ≤ 75 75 < x ≤ 87 87 < x ≤ 105 105 < x ≤ 135 >135 Dummy Q0 Q1 Q1.5 Q3 Q6 Q101 1 No lateral impact test is required for size range over 135 cm until Q10 dummy injury criteria for the lateral impact test are established. Where the Enhanced Child Restraint System requires substantial modification for different sizes (e.g., convertible Enhanced Child Restraint System) or if the size range cover more than 3 size ranges a relevant intermediate dummy(ies) shall be tested in addition to the dummy(ies) defined above.
Sample 1Sample 2Sample 3See All (6)
Size indication. The dynamic tests shall be conducted with the largest dummy and the smallest dummy as defined in the following tables according to the size range indicated by the manufacturer for the Enhanced Child Restraint System. Deleted: CRS‐60‐01e.docx2¶ Formatted: English (U.K.) Formatted: English (U.K.) Table 7 Selection criteria for the dummy according to the range Size range indication (incm) ≤ 60 60 < x ≤ 75 75 < x ≤ 87 87 < x ≤105 105 < x ≤ 125 >125 Dummy Q0 Q1 Q1.5 Q3 Q62 Q101 1 No lateral impact test using the Q10 dummy is required for i-Size booster seats with a sizerange upper limit between125 cm and 135 cm. 2 ECRS shall not be approved only on the base of Q3 test results in non‐integral configuration Where the Enhanced Child Restraint System requires substantial modification for different sizes (e.g., convertible Enhanced Child Restraint System) or if the size range cover more than 3 size ranges a relevant intermediate dummy(ies) shall be tested in addition to the dummy(ies) defined above.
Sample 1
Size indication. The dynamic tests shall be conducted with the largest dummy and the smallest dummy as defined in the following tables according to the size range indicated by the manufacturer for the Enhanced Child Restraint System. Table 7 Selection criteria for the dummy according to the range Size range indication (in cm) ≤ 60 60 < x ≤ 75 75 < x ≤ 87 87 < x ≤ 105 105 < x ≤ 125 >125 1 No lateral impact test using the Q10 dummy is required for i-Size booster seats with a size range upper limit between 125 cm and 135 cm. 2 ECRS shall not be approved only on the base of Q3 test results in non-integral configuration Where the Enhanced Child Restraint System requires … defined above." Paragraphs 7.3. to 7.3.3., amend to read:
Sample 1

Related to Size indication

  • Geographical Indications 1. Each Party shall recognise that geographical indications may be protected through a trade xxxx or sui generis system or other legal means in accordance with its laws and regulations.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Regulatory Approval 25.1 The Parties understand and agree that this Agreement and any amendment or modification hereto will be filed with the Commission for approval in accordance with Section 252 of the Act and may thereafter be filed with the FCC. The Parties believe in good faith and agree that the services to be provided under this Agreement are in the public interest. Each Party covenants and agrees to fully support approval of this Agreement by the Commission or the FCC under Section 252 of the Act without modification.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Performance Indicators The HSP’s delivery of the Services will be measured by the following Indicators, Targets and where applicable Performance Standards. In the following table: n/a meanç ‘not-appIicabIe’, that there iç no defined Performance Standard for the indicator for the applicable year. tbd means a Target, and a Performance Standard, if applicable, will be determined during the applicable year. INDICATOR CATEGORY INDICATOR P = Performance Indicator E = Explanatory Indicator M = Monitoring Indicator 2019/20 PERFORMANCE TARGET STANDARD Organizational Health and Financial Indicators Debt Service Coverage Ratio (P) 1 c1 Total Margin (P) 0 cO Coordination and Access Indicators Percent Resident Days – Long Stay (E) n/a n/a Wait Time from LHIN Determination of Eligibility to LTC Home Response (M) n/a n/a Long-Term Care Home Refusal Rate (E) n/a n/a SCHEDULE D — PERFORMANCE 2/3 INDICATOR CATEGORY Quality and Resident Safety Indicators INDICATOR P = Performance Indicator E = Explanatory Indicator M = Monitoring Indicator Percentage of Residents Who Fell in the Last 30 days (M) 2019/20 PERFORMANCE TARGET STANDARD n/a n/a Percentage of Residents Whose Pressure Ulcer Worsened (M) n/a n/a Percentage of Residents on Antipsychotics Without a Diagnosis of Psychosis (M) n/a n/a Percentage of Residents in Daily Physical Restraints (M) n/a n/a SCHEDULE D — PERFORMANCE 2.0 LHIN-Specific Performance Obligations 3/3

  • For clarity the time allowances provided in clause 2.10 shall operate to reduce the maximum timetabled classroom teaching time specified in clause 4.2 of this agreement.

  • Performance indicators and targets The purpose of the innovation performance indicators and targets is to assist the University and the Commonwealth in monitoring the University's progress against the Commonwealth's objectives and the University's strategies for innovation. The University will report principal performance information and aim to meet the innovation performance indicators and targets set out in the following tables.

  • Development Schedule The Project shall substantially comply with the specific timetables and triggers for action set forth in Article 5 of this Agreement. The parties acknowledge that, as provided in G.S. 160A-400.25(b), the failure to meet a commencement or completion date shall not, in and of itself, constitute a material breach of this Agreement pursuant to G.S. 160A-400.27 but must be judged based upon the totality of the circumstances.

Time is Money Join Law Insider Premium to draft better contracts faster.